Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease

This article was originally published here

NLY01 is also being evaluated in patients with Parkinson’s disease in a Phase 2 trial initiated in February 2020. “Initiation of this Phase 2 study in Alzheimer’s disease

The post Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply